cardiovascular-agents and flosequinan

Large drug trials have become very important to determine which drugs should be used in the treatment of patients with chronic heart failure (CHF). When these trials showed "positive" results, publication of the data soon followed, leading to a substantial impact on prescription patterns. In the case of "negative" results, many times they were not published, or were reported as an abstract or as short paper disclosing only the main findings. In this article we will discuss some of these trials that were conducted in the last 10 years, since we believe they may provide insight into the pathophysiology and treatment options in CHF.

Topics: Bosentan; Cardiovascular Agents; Deoxyepinephrine; Heart Failure; Humans; Imidazoles; Mibefradil; Pyrazines; Quinolines; Sulfonamides; Xamoterol

Topics: Animals; Calcium Channel Agonists; Cardiac Glycosides; Cardiovascular Agents; Catecholamines; Cyclic AMP; Heart Diseases; Heart Failure; Hemodynamics; Humans; Phosphodiesterase Inhibitors; Quinolines; Sodium Channels; Vasodilator Agents

Topics: Animals; Cardiovascular Agents; Cats; Dogs; Humans; Quinolines; Quinolones; Rats; Structure-Activity Relationship; Vasodilator Agents

Topics: Amlodipine; Bisoprolol; Cardiovascular Agents; Cardiovascular Diseases; Humans; Quinolines; Sotalol; Vasodilator Agents